Trastuzumab Emtansine

• HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc… Not authorised
  2024-516253-49-00 Phase II 1 country Institut Jules Bordet
• Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced br… Pending
  2024-518026-32-00 Phase III 6 countries Fondazione Michelangelo
• A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit… Recruiting
  2025-523204-68-00 Phase II 3 countries Jazz Pharmaceuticals Ireland Limited
• HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc… Recruiting
  2024-516253-49-01 Phase II 2 countries Institut Jules Bordet
• HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting
  2025-521040-37-00 Phase III 4 countries Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques Augus…
• Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps … Recruiting
  2023-509566-38-00 Phase I/II 5 countries Boehringer Ingelheim International GmbH
• Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting
  2023-509811-98-00 Phase II 1 country Unicancer
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tu… Ended
  2023-508194-89-00 Phase II 5 countries F. Hoffmann-La Roche AG
• Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2) Ended
  2023-508738-32-00 Phase II 4 countries Medica Scientia Innovation Research S.L.
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended
  2023-507961-24-00 Phase III 13 countries Daiichi Sankyo Inc.
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… Ended
  2023-503568-18-00 Phase III 14 countries F. Hoffmann-La Roche AG
• A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast… Ended
  2024-514733-38-00 Phase III 8 countries Seagen Inc.
• Image‐guided de‐escalation of neoadjuvant chemotherapy in HER2‐positive breast cancer: the TRAIN‐3 study Ended
  2024-516205-23-00 Phase II 1 country BOOG Study Center B.V.
• Testing a new targeted therapy trastuzumab deruxtecan (DS-8201a) against ado-trastuzumab emtansine (T-DM1) for patients with advanced stage … Ended
  2024-511204-16-00 Phase III 4 countries Daiichi Sankyo Inc.
• PREDIX HER2 - preoperative treatment of HER2 positive breast cancer Ended
  2023-508411-23-00 Phase II 1 country Karolinska University Hospital
• An Extension Study of trastuzumab emtansine administered as a single agent or in combination with other anti-cancer therapies in patients pr… Ended
  2023-503479-79-00 Phase II 5 countries F. Hoffmann-La Roche AG
• A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Admi… Ended
  2023-506380-33-00 Phase III 3 countries F. Hoffmann-La Roche AG
• A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Ended
  2024-519070-39-00 Phase II 1 country Region Hovedstaden

Showing 1–18 of 18 trials